NCT01916122View on ClinicalTrials.gov

Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status

EARLY_PHASE1CompletedINTERVENTIONAL
Enrollment

54

Participants

Timeline

Start Date

August 1, 2013

Primary Completion Date

April 3, 2024

Study Completion Date

April 3, 2024

Conditions
Breast Cancer
Interventions
DRUG

Fluorestradiol (FES)

PROCEDURE

PET/CT Imaging

Trial Locations (1)

10065

Memorial Sloan Kettering Cancer Center, New York

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER

NCT01916122 - Fluorestradiol (FES) PET/CT for Imaging Estrogen Receptor Status | Biotech Hunter | Biotech Hunter